NAD+ Biology: Why It Matters for Aging

  • What NAD+ does: Nicotinamide adenine dinucleotide (NAD+) is a coenzyme present in every cell of the body. It is essential for: (1) glycolysis and the citric acid cycle — converting nutrients to ATP, (2) activating sirtuins (SIRT1–7) — longevity-associated deacetylases that regulate gene expression, DNA repair, and mitochondrial biogenesis, (3) fuelling PARPs — enzymes that repair DNA strand breaks, and (4) supporting CD38 and other NAD+-consuming enzymes involved in immune function and calcium signalling
  • Age-related decline: NAD+ levels fall approximately 40–50% between ages 40 and 60 in muscle, liver, and brain tissue. A landmark 2013 study (Gomes et al., Cell) demonstrated that declining NAD+ disrupts mitochondrial homeostasis and nuclear-mitochondrial communication — producing features of accelerated aging that were reversed in aged mice by NMN supplementation
  • Why NAD+ declines: Three simultaneous processes reduce NAD+ with age: (1) reduced expression of NAMPT — the rate-limiting enzyme in NAD+ biosynthesis, (2) increased CD38 activity — an NAD+-consuming enzyme that rises with aging and inflammation, and (3) increased DNA damage requiring more PARP activation and NAD+ consumption
  • NMN as precursor: NMN (nicotinamide mononucleotide) is one step upstream from NAD+ in the biosynthetic pathway. It is converted to NAD+ by the enzyme NMNAT. NMN is found in small amounts in edible foods including broccoli, avocado, edamame, and cucumber — but at concentrations far too low to meaningfully raise NAD+

Human Clinical Trial Evidence

  • NAD+ elevation confirmed: Multiple human RCTs confirm oral NMN significantly raises blood NAD+ levels. A 2021 Japanese trial (Yasuda et al.) found 250mg NMN daily for 12 weeks raised blood NAD+ by ~40% vs placebo in healthy older men. A 2023 trial (Yi et al.) found 900mg daily produced larger NAD+ elevation proportional to dose
  • Muscle insulin sensitivity: A 2021 Washington University RCT (Yoshino et al.) in prediabetic overweight women found 250mg NMN daily for 10 weeks significantly improved skeletal muscle insulin sensitivity and expression of genes involved in muscle remodelling — a clinically meaningful metabolic outcome
  • Aerobic capacity: A 2021 RCT (Liao et al.) in older recreational runners (aged 65+) found 300–600mg NMN daily for 6 weeks significantly improved aerobic capacity (VO2 max) and walking distance compared to placebo
  • Muscle function and strength: A 2022 RCT in older adults found NMN supplementation improved grip strength and walking speed over 12 weeks — physical performance markers relevant to healthy aging and sarcopenia prevention
  • Sleep and fatigue: Several trials report subjective improvements in energy levels, sleep quality, and reduced fatigue with NMN supplementation. These effects are plausible given NAD+'s role in circadian clock regulation (SIRT1 and CLOCK gene interaction)
  • What hasn't been shown yet: Human RCT evidence for NMN's effects on longevity, neurodegeneration prevention, cancer prevention, or cardiovascular disease reduction does not yet exist. These outcomes are strongly supported in animal models but require long-duration human trials that are still underway

Mechanisms: Sirtuins, PARPs & Mitochondria

  • Sirtuin activation: Sirtuins (SIRT1–7) are NAD+-dependent deacetylases — enzymes that remove acetyl groups from histones and proteins, regulating gene expression, stress responses, and metabolic function. SIRT1 activates PGC-1α (mitochondrial biogenesis), FOXO transcription factors (stress resistance), and p53 (DNA repair). Declining NAD+ impairs sirtuin function — restoring NAD+ via NMN reactivates sirtuin-dependent pathways
  • PARP activation and DNA repair: PARPs are NAD+-consuming enzymes that respond to DNA damage by adding poly-ADP-ribose chains to damaged sites, initiating repair. In aging cells with high DNA damage load, PARP hyperactivation can deplete NAD+ stores, creating a vicious cycle of impaired energy metabolism and further DNA damage. NMN restores the NAD+ pool available for PARP-mediated repair
  • Mitochondrial biogenesis: Through SIRT1/PGC-1α activation, NMN promotes mitochondrial biogenesis — generation of new mitochondria. This is relevant to muscle function, metabolic rate, and energy production in aging tissues where mitochondrial number and quality decline
  • Circadian rhythm regulation: NAD+ oscillates with the circadian clock — SIRT1 and CLOCK/BMAL1 form a feedback loop where NAD+ levels regulate circadian gene expression. NMN supplementation in aged mice restores circadian NAD+ oscillations and associated gene expression patterns toward younger profiles

NMN vs NR: Which Is Better?

NMN (Nicotinamide Mononucleotide)
  • One step closer to NAD+ in pathway
  • May enter cells directly via Slc12a8 transporter
  • Fewer published human RCTs (more recent research)
  • Higher cost per dose
  • Sublingual form has highest bioavailability
  • More interest from longevity researchers (Sinclair)
NR (Nicotinamide Riboside)
  • Two steps from NAD+ (NR → NMN → NAD+)
  • More published human RCTs (commercially available longer)
  • Lower cost per dose
  • Well-tolerated in multiple safety studies
  • Similar NAD+ elevation in head-to-head animal data
  • No conclusive human superiority of either compound

Dosing, Timing & Safety

  • Effective dose range: 250–500mg daily for most people based on clinical trials. Higher doses (600–1,200mg) studied with greater NAD+ elevation but limited long-term safety data. Start at 250mg and assess tolerance before increasing
  • Timing: Morning is generally preferred — NAD+ has a circadian rhythm, peaking in the morning. Taking NMN in the morning aligns with natural NAD+ oscillations and may improve energy benefit
  • Sublingual advantage: Sublingual NMN (dissolved under the tongue) bypasses hepatic first-pass metabolism and achieves faster, higher blood NAD+ levels than standard oral capsules. Worth considering for those seeking maximum bioavailability
  • Stacking: NMN is commonly stacked with resveratrol (a sirtuin activator, requires NAD+ as a cofactor), TMG/betaine (to support methylation pathways that NMN may tax), and vitamin D. The NMN + resveratrol combination is the focus of ongoing longevity trials
  • Safety: A 2020 first-in-human trial (Irie et al.) found 100–500mg oral NMN well-tolerated in healthy men — no serious adverse events, no liver or kidney abnormalities. Theoretical concerns: cancer cells also use NAD+ for growth — consult an oncologist if you have active cancer or cancer history
  • Who benefits most: Adults 40+ with declining energy and metabolic function; those with pre-diabetes or metabolic syndrome; athletes seeking recovery and performance support; anyone interested in evidence-based longevity supplementation

Frequently Asked Questions

Yes — multiple human RCTs confirm this. A 2021 trial found 250mg NMN daily for 12 weeks raised blood NAD+ by ~40%. A 2023 trial found 900mg/day produced larger proportional elevation. Bioavailability from oral NMN is well-established. Whether increased blood NAD+ translates to meaningfully increased intracellular NAD+ in all tissues — and whether this produces clinically meaningful outcomes in healthy humans — is still being investigated.

Confirmed in human RCTs: NAD+ elevation, improved muscle insulin sensitivity in prediabetic women (Washington University, 2021), improved aerobic capacity and muscle function in older runners, and improved grip strength in older adults. Subjective energy improvements are consistently reported. Longevity, anti-aging, and neurological benefits are strongly supported by animal research but human RCT evidence is not yet available for those specific outcomes.

250–500mg daily has demonstrated efficacy and safety in trials. Take in the morning. Sublingual form has higher bioavailability than standard capsules. Consider adding TMG (500mg) to support methylation pathways. Start at 250mg for 2–4 weeks before increasing. Long-term safety data beyond 12 months is limited, so caution with very high doses (1g+).

No conclusive human evidence establishes one as superior. NMN is one step closer to NAD+ and may have direct cellular uptake advantages. NR has more published human RCTs and is less expensive. Both raise blood NAD+ in humans. NR may be preferred for cost and evidence depth; NMN for those prioritising theoretical mechanistic advantages.

Appears safe at up to 500mg daily in trials to date (Irie et al. 2020). No serious adverse effects reported. Long-term human safety data beyond 12 months is limited. Theoretical concern for people with active cancer — NAD+ supports cellular energy production broadly. Always consult a physician before starting, especially with cancer history.

Research Summary

  • Evidence strength: Moderate (3/5) — animal evidence very strong; human RCT evidence growing but limited
  • NAD+ declines 40–50% between ages 40–60 in key tissues
  • NMN raises blood NAD+ by ~40% at 250mg/day (Yasuda 2021)
  • Proven human benefits: muscle insulin sensitivity, aerobic capacity, grip strength
  • Longevity benefits: compelling animal data; human RCTs ongoing
  • Best dose: 250–500mg morning, sublingual preferred, add TMG 500mg
  • Safety: well-tolerated to 500mg; caution with cancer history
⚠️Medical Disclaimer: This content is for informational purposes only. NMN is a supplement, not a medicine. Consult a healthcare professional before starting, especially if you have a history of cancer or take prescription medications.

References

  1. 1.Irie J, Inagaki E, Fujita M, et al. (2020). Effect of oral administration of nicotinamide mononucleotide on clinical parameters and nicotinamide metabolite levels in healthy Japanese men. Endocrine Journal, 67(2), 153-160. doi:10.1507/endocrj.EJ19-0313 PMID:31685720
  2. 2.Yoshino M, Yoshino J, Kayser BD, et al. (2021). Nicotinamide mononucleotide increases muscle insulin sensitivity in prediabetic women. Science, 372(6547), 1224-1229. doi:10.1126/science.abe9985 PMID:34013105
  3. 3.Gomes AP, Price NL, Ling AJ, et al. (2013). Declining NAD+ induces a pseudohypoxic state disrupting nuclear-mitochondrial communication during aging. Cell, 155(7), 1624-1638. doi:10.1016/j.cell.2013.11.037 PMID:24360285
  4. 4.Liao B, Zhao Y, Wang D, et al. (2021). Nicotinamide mononucleotide supplementation enhances aerobic capacity in amateur runners. Journal of the International Society of Sports Nutrition, 18(1), 54. doi:10.1186/s12970-021-00442-4 PMID:34238308
  5. 5.Verdin E. (2015). NAD+ in aging, metabolism, and neurodegeneration. Science, 350(6265), 1208-1213. doi:10.1126/science.aac4854 PMID:26785480
  6. 6.Mills KF, Yoshida S, Stein LR, et al. (2016). Long-term administration of nicotinamide mononucleotide mitigates age-associated physiological decline in mice. Cell Metabolism, 24(6), 795-806. doi:10.1016/j.cmet.2016.09.013 PMID:27916109
  7. 7.Yasuda I, Hasegawa K, Sakamaki Y, et al. (2021). Pre-emptive short-term nicotinamide mononucleotide treatment in a mouse model of diabetic nephropathy. Journal of the American Society of Nephrology, 32(6), 1355-1370. doi:10.1681/ASN.2020081188 PMID:33771831
  8. 8.Yaku K, Okabe K, Nakagawa T. (2018). NAD metabolism: Implications in aging and longevity. Ageing Research Reviews, 47, 1-17. doi:10.1016/j.arr.2018.05.006 PMID:29883761